Editorial
doi: 10.3390/jcm11175250.
Statin Intolerance-We Know Everything, We Know Nothing
Affiliations
- PMID: 36079180
- PMCID: PMC9457222
- DOI: 10.3390/jcm11175250
Item in Clipboard
Editorial
Statin Intolerance-We Know Everything, We Know Nothing
J Clin Med.
.
Abstract
Lipid disorders are the most common risk factors of cardiovascular disease (CVD) [...].
Conflict of interest statement
M.B.: speakers bureau: Amgen, Daichii Sankyo, Herbapol, Kogen, KRKA, Polpharma, Mylan/Viatris, Novartis, Novo-Nordisk, Sanofi, Teva, Zentiva; consultant to Adamed, Amgen, Daichii Sankyo, Esperion, Freia Pharmaceuticals, Novartis, Polfarmex, Sanofi; grants from Amgen, Mylan/Viatris, Sanofi and Valeant; CMO at the Nomi Biotech Corporation.
Similar articles
-
Adherence to statin therapy: it seems we know everything, yet we do nothing.Eur Heart J Open. 2022 Oct 26;2(6):oeac071. doi: 10.1093/ehjopen/oeac071. eCollection 2022 Nov. Eur Heart J Open. 2022. PMID: 36440352 Free PMC article. No abstract available.
-
Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel.Expert Opin Drug Saf. 2015 Jun;14(6):935-55. doi: 10.1517/14740338.2015.1039980. Epub 2015 Apr 24. Expert Opin Drug Saf. 2015. PMID: 25907232
-
Clinicians learn less and less about more and more until they know nothing about everything; researchers learn more and more about less and less until they know everything about nothing: discuss.Behav Brain Sci. 2012 Oct;35(5):358-9. doi: 10.1017/S0140525X12001367. Behav Brain Sci. 2012. PMID: 23095379
-
Statin intolerance - a question of definition.Expert Opin Drug Saf. 2017 Jan;16(1):55-63. doi: 10.1080/14740338.2017.1238898. Epub 2016 Sep 27. Expert Opin Drug Saf. 2017. PMID: 27645111 Review.
-
Statin Intolerance: the Clinician's Perspective.Curr Atheroscler Rep. 2015 Dec;17(12):69. doi: 10.1007/s11883-015-0552-3. Curr Atheroscler Rep. 2015. PMID: 26490078 Free PMC article. Review.
References
-
- Roth G.A., Mensah G.A., Johnson C.O., Addolorato G., Ammirati E., Baddour L.M., Barengo N.C., Beaton A.Z., Benjamin E.J., Benziger C.P., et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update from the GBD 2019 Study. J. Am. Coll. Cardiol. 2020;76:2982–3021. doi: 10.1016/j.jacc.2020.11.010. - DOI - PMC - PubMed
-
- Ray K.K., Molemans B., Schoonen W.M., Giovas P., Bray S., Kiru G., Murphy J., Banach M., De Servi S., Gaita D., et al. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: The DA VINCI study. Eur. J. Prev. Cardiol. 2021;28:1279–1289. doi: 10.1093/eurjpc/zwaa047. - DOI - PubMed
-
- Vrablik M., Seifert B., Parkhomenko A., Banach M., Jóźwiak J.J., Kiss R.G., Gaita D., Rašlová K., Zachlederova M., Bray S., et al. Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study. Atherosclerosis. 2021;334:66–75. doi: 10.1016/j.atherosclerosis.2021.08.035. - DOI - PubMed
-
- Banach M., Penson P.E., Fras Z., Vrablik M., Pella D., Reiner Ž., Nabavi S.M., Sahebkar A., Kayikcioglu M., Daccord M. Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic. Pharmacol. Res. 2020;158:104891. doi: 10.1016/j.phrs.2020.104891. - DOI - PMC - PubMed
-
- Vahedian-Azimi A., Mohammadi S.M., Beni F.H., Banach M., Guest P.C., Jamialahmadi T., Sahebkar A. Improved COVID-19 ICU admission and mortality outcomes following treatment with statins: A systematic review and meta-analysis. Arch. Med. Sci. 2021;17:579–595. doi: 10.5114/aoms/132950. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
